Prodigiosin Sensitizes Sensitive and Resistant Urothelial Carcinoma Cells to Cisplatin Treatment

Cisplatin-based treatment is the standard of care therapy for urothelial carcinomas. However, complex cisplatin resistance mechanisms limit the success of this approach. Both apoptosis and autophagy have been shown to contribute to this resistance. Prodigiosin, a secondary metabolite from various ba...

Descripción completa

Detalles Bibliográficos
Autores principales: Berning, Lena, Schlütermann, David, Friedrich, Annabelle, Berleth, Niklas, Sun, Yadong, Wu, Wenxian, Mendiburo, María José, Deitersen, Jana, Brass, Hannah U. C., Skowron, Margaretha A., Hoffmann, Michèle J., Niegisch, Günter, Pietruszka, Jörg, Stork, Björn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957586/
https://www.ncbi.nlm.nih.gov/pubmed/33673611
http://dx.doi.org/10.3390/molecules26051294

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957586/
https://www.ncbi.nlm.nih.gov/pubmed/33673611
http://dx.doi.org/10.3390/molecules26051294

Ejemplares similares